Bookimed does not add extra charges for Thrombocytopenia treatment prices. The rates come from the clinics' official price lists. You pay directly at the clinic for your treatment upon your arrival to the country.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Thrombocytopenia treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Thrombocytopenia treatment journey.
| Turkey | Austria | Spain |
Hospital Sant Joan de Déu (Barcelona, Spain) accepts children for treatment from the infant age to 21. The Hospital belongs to Top-5 medical institutions in Europe and is recognized as the most authoritative one in the field of pediatric oncology treatment. The Center has its own Laboratory for Molecular Medicine where innovative therapeutic methods are developed.
Hospital HM Sanchinarro is a private multi-specialty medical center located in Madrid, Spain. The clinic's team specializes in neurosurgery, oncology, urology, and surgery. Hospital HM Sanchinarro serves only adults. 400,000 patients choose Hospital HM Sanchinarro to get medical care every year. They are mainly patients from Europe & Commonwealth, Arab League States, and Russian-speaking countries.
Clinica Universidad de Navarra (CUN) is the best private Spanish hospital in 2018 according to MERCO (monitoring organization of medical reputation).
Navarra is a leading sarcoma center. 74% of patients get cured of bone sarcoma; and in up to 95% of cases, an affected limb is preserved.
Oncology, Onco-Hematology, Organ Transplant, Neurosurgery, Cardiac Surgery are the primary specialties in Navarra Hospital.
Hospital de Navarra is the 1st in Spain that has received JCI, the US certificate for the high quality of medical services.
Over 700,000 patients from 70 countries have been treated at Navarra.
Professor Bosch is a highly reputed leader in Chronic Lymphocytic Leukemia (CLL) and conducts clinical and basic research on CLL and other lymphoproliferative disorders, focusing on the molecular pathogenesis of CLL and new therapeutic approaches. He has published over 100 articles in prestigious journals and is a professor of haematology at the Vall d'Hebron University Hospital of Barcelona.